May 2, 2007 |
Genentech Inc. and Biogen Idec Inc. said their Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potential new way of treating the progressive neurological disease. The biotechnology companies said the Phase II trial involved 104 patients with the most common "relapsing-remitting" form of multiple sclerosis -- in which patients have varying levels of recovery and periods of remission between flare-ups of the autoimmune disease.
March 10, 2005 |
Three senior researchers at the center of a controversy at the National Institutes of Health over moonlighting for the pharmaceutical industry are leaving the government, officials said. The departures come at a time when the NIH is implementing tougher conflict-of-interest rules that prohibit all agency employees from accepting consulting fees, stock options or any compensation from the industry. The three departing researchers are: Dr. H. Bryan Brewer Jr.
October 4, 2002 |
The government has created a genetically engineered anthrax vaccine that promises to cut in half the six shots now needed for protection, and chosen two biotechnology companies to begin testing it. The $22.5-million contract award will allow California-based VaxGen Inc. and Britain's Avecia to test the experimental vaccine on people to see if it is safe and, if so, to see if it provides protection against the deadly bacteria.
August 29, 2006 |
Biotechnology companies Genentech Inc. and Biogen Idec Inc. said their cancer drug Rituxan showed hints of effectiveness against multiple sclerosis in a small mid-stage trial. The study involved 104 adults with the most common form of multiple sclerosis. It showed a statistically significant reduction among those given Rituxan in the total number of brain lesions, South San Francisco-based Genentech said. Rituxan is one of the biggest-selling treatments for non-Hodgkin's lymphoma.
June 14, 1985
The Rockville, Md., biotechnology firm said its contract to produce ingredients for Searle's popular sweetener, aspartame, will not be renewed when it expires Oct. 31. Genex has often been listed as one of the nation's five most promising biotechnology companies. Its sales to Searle in 1984 accounted for $20.2 million of Genex's product sales of $20.6 million and 58% of the company's total revenue of $34.8 million. Both companies declined to comment on why the contract will not be extended.